Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
3
75%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

completed375%
recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
completedphase_1

A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors

NCT04175847
completedphase_2

RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

NCT06173037
completedphase_1

A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours

NCT05508334
recruitingphase_1

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

NCT05804526

Clinical Trials (4)

Showing 4 of 4 trials
NCT04175847Phase 1

A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors

Completed
NCT06173037Phase 2

RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Completed
NCT05508334Phase 1

A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours

Completed
NCT05804526Phase 1

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4